Fabricio Simao
Senior Principal Scientist Quiver Bioscience
Seminars
Thursday 24th September 2026
NaV1.7 Targeting Antisense Oligonucleotides: Emerging Modalities for Pain & Pipeline Development
11:00 am
- Utilizing ASOs as a novel way to modulate NaV1.7, which can circumvent the existing issues with small molecule inhibitors (e.g. autonomic side effects)
- Exploring how Quiver’s integrated platform based on all-optical electrophysiology and machine learning has led to identifying novel candidate molecules alongside therapeutic targets
- Demonstrating how Quiver’s platform can enrich the genetic medicine drug candidates with maximized therapeutic index
Thursday 24th September 2026
Panel: Comparing Modality Selection Decisions to Match Biology & Indication Requirements
12:00 pm
- Examining how biology, delivery constraints & safety risk shaped final modality choices
- Weighing durability, tissue access, reversibility & tolerability across competing strategies
- Identifying modality decision principles that remain consistent across CNS & peripheral programs
